Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CWBRNASDAQ:DRMANYSE:MTNBNASDAQ:ONCO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/ADRMADermata Therapeutics$0.73-5.2%$0.78$0.66▼$5.00$4.68M0.571.18 million shs103,591 shsMTNBMatinas Biopharma$0.88-15.4%$0.70$0.47▼$9.60$4.48M1.28217,386 shs162,392 shsONCOOnconetix$0.07+7.7%$0.07$0.05▼$14.00$4.78M3.58.64 million shs69.30 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCWBRCohBar0.00%0.00%0.00%0.00%-47.44%DRMADermata Therapeutics+3.20%+9.32%-2.52%-34.41%-75.27%MTNBMatinas Biopharma+18.17%+25.29%+64.77%+88.07%+460.04%ONCOOnconetix-15.89%-6.39%-1.71%-47.00%-98.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/ADRMADermata Therapeutics3.0654 of 5 stars3.55.00.00.03.60.00.6MTNBMatinas Biopharma0.8776 of 5 stars0.05.00.00.01.90.00.6ONCOOnconetix0.7144 of 5 stars0.04.00.00.02.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCWBRCohBar 0.00N/AN/AN/ADRMADermata Therapeutics 3.00Buy$3.00308.72% UpsideMTNBMatinas Biopharma 2.00HoldN/AN/AONCOOnconetix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CWBR, ONCO, DRMA, and MTNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCWBRCohBarN/AN/AN/AN/A$5.27 per shareN/ADRMADermata TherapeuticsN/AN/AN/AN/A$24.24 per shareN/AMTNBMatinas Biopharma$1.10M4.07N/AN/A$4.43 per share0.20ONCOOnconetix$2.52M1.89N/AN/A$3.01 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/ADRMADermata Therapeutics-$7.80M-$16.41N/A∞N/AN/A-247.39%-179.72%N/AMTNBMatinas Biopharma-$22.94M-$3.86N/A∞N/AN/A-123.06%-94.28%N/AONCOOnconetix-$37.41MN/A0.00∞N/A-2,758.89%N/A-48.09%6/12/2025 (Estimated)Latest CWBR, ONCO, DRMA, and MTNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q1 2025ONCOOnconetixN/A$0.25N/A-$0.53N/AN/A5/14/2025Q1 2025DRMADermata Therapeutics-$0.45-$0.45N/A-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCWBRCohBarN/AN/AN/AN/AN/ADRMADermata TherapeuticsN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCWBRCohBarN/AN/AN/ADRMADermata TherapeuticsN/A3.443.44MTNBMatinas BiopharmaN/A5.535.53ONCOOnconetixN/A0.060.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCWBRCohBar2.47%DRMADermata Therapeutics8.67%MTNBMatinas Biopharma11.77%ONCOOnconetix23.89%Insider OwnershipCompanyInsider OwnershipCWBRCohBar6.51%DRMADermata Therapeutics9.40%MTNBMatinas Biopharma4.60%ONCOOnconetix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCWBRCohBar102.91 millionN/ANot OptionableDRMADermata Therapeutics86.38 million1.85 millionNot OptionableMTNBMatinas Biopharma305.09 million4.60 millionN/AONCOOnconetix1264.55 million57.17 millionN/ACWBR, ONCO, DRMA, and MTNB HeadlinesRecent News About These CompaniesOnconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of StockholdersJune 11 at 11:30 AM | globenewswire.comOnconetix faces potential Nasdaq delisting over filing delaysMay 24, 2025 | investing.comOnconetix receives additional delisting notice from NasdaqMay 23, 2025 | finance.yahoo.comOnco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision OncologyMay 22, 2025 | accessnewswire.comOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqMay 22, 2025 | globenewswire.comOnco-Innovations Uplists to Cboe CanadaMay 22, 2025 | businesswire.comOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqApril 30, 2025 | globenewswire.comOnconetix faces third delisting threat since 2022 IPOApril 21, 2025 | bizjournals.comOnco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP TechnologyApril 17, 2025 | accessnewswire.comOnco-Innovations Announces Private PlacementApril 16, 2025 | accessnewswire.comOnconetix Inks Letter Of Intent For Potential Business Combination With OcuvexApril 10, 2025 | nasdaq.comFive things you need to know today, and calming irrational fearsApril 9, 2025 | bizjournals.comOnconetix signs non-binding LOI for potential combination with OcuvexApril 9, 2025 | markets.businessinsider.comCincinnati's Onconetix pursuing merger deal with drug development firmApril 8, 2025 | bizjournals.comOnconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.April 8, 2025 | markets.businessinsider.com🌱 Cincinnati's arena debate heats upApril 6, 2025 | msn.comAnother top executive departs Cincinnati public firmApril 6, 2025 | local12.comOnconetix executive chairman resigns in latest leadership exit; interim CFO named new top leaderApril 5, 2025 | bizjournals.comOnconetix Names Interim CFO Karina Fedasz as Interim CEOApril 3, 2025 | marketwatch.comOnco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety ProfileMarch 26, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCWBR, ONCO, DRMA, and MTNB Company DescriptionsCohBar NASDAQ:CWBR$0.41 0.00 (0.00%) As of 01/23/2025CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Dermata Therapeutics NASDAQ:DRMA$0.73 -0.04 (-5.17%) As of 03:50 PM EasternDermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Matinas Biopharma NYSE:MTNB$0.88 -0.16 (-15.38%) As of 04:00 PM EasternMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.Onconetix NASDAQ:ONCO$0.07 +0.01 (+7.70%) As of 04:00 PM EasternOnconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
